Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients
Ebru Sevinc Ok1, Gulay Asci, Huseyin Toz
1Division of Nephrology, Ege University, Izmir, Turkey, Division of Nephrology, University of Heidelberg, Heidelberg, Germany, and Division of Nephrology, Istanbul University, Istanbul, Turkey.
Insights
Higher glycated hemoglobin (HbA1c) levels in non-diabetic hemodialysis patients predict increased mortality. This study found upper normal HbA1c is linked to higher cardiovascular and overall death risk.
Area of Science:
- Nephrology
- Endocrinology
- Clinical Chemistry
Background:
- Glycated hemoglobin (HbA1c) predicts mortality in diabetic and non-diabetic individuals.
- The prognostic value of HbA1c in non-diabetic hemodialysis patients remains unclear.
Purpose of the Study:
- To prospectively investigate the association between HbA1c levels and all-cause and cardiovascular mortality.
- Focus on a large cohort of prevalent non-diabetic hemodialysis patients.
Main Methods:
- Quarterly HbA1c measurements in 489 non-diabetic hemodialysis patients.
- Follow-up for all-cause and cardiovascular mortality over 3 years.
Main Results:
- Higher HbA1c tertiles (> 5.04%) were significantly associated with increased overall (HR=3.60) and cardiovascular mortality (HR=6.66).
- Lower HbA1c tertiles (< 4.69%) showed a trend towards higher overall mortality (HR=2.26).
- Kaplan-Meier analysis indicated poorer survival in the lowest and highest HbA1c groups.
Conclusions:
- Upper-normal range HbA1c levels are independently linked to higher cardiovascular and overall mortality.
- Lower HbA1c levels did not show a significant association with mortality in this cohort.
Aims:
Besides diabetic patients, glycated hemoglobin (HbA1c) levels have been reported to predict mortality in non-diabetics patients. However, the importance of HbA1c levels in non-diabetic hemodialysis patients still remains unknown. Thus, we aimed to prospectively investigate the impact of HbA1c on all-cause and cardiovascular mortality in a large group of prevalent non-diabetic hemodialysis patients.
Methods:
HbA1c was measured quarterly in 489 non-diabetic prevalent hemodialysis patients. Overall and cardiovascular mortality were evaluated over a 3 year follow-up.
Results:
Mean HbA1c level was 4.88 ± 0.46% (3.5 - 6.9%). During the 28.3 ± 10.6 months follow-up period, 67 patients (13.7%) died; 31 from cardiovascular causes. In Kaplan-Meier analysis, patients in the lowest (< 4.69%) and highest HbA1c (> 5.04%) tertiles had poorer overall survival compared to the middle HbA1c tertile (p < 0.001). Adjusted Cox-regression analysis revealed that the highest HbA1c tertile was associated with both overall (HR = 3.60, 95% CI 1.57 - 8.27, p = 0.002) and cardiovascular (HR = 6.66, 95% CI 1.51 - 29.4; p = 0.01) mortality. Also, low HbA1c levels tended to be associated with overall mortality (HR = 2.26, 95% CI 0.96 - 5.29, p = 0.06).
Conclusion:
Upper normal HbA1c levels are independently associated with cardiovascular and overall mortality in non-diabetic hemodialysis patients, whereas lower HbA1c levels are not.
More Related Videos
04:36Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Diabetic Nephropathy
Hyperglycemia
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Hemodialysis II: Procedure and Complications
Diabetes: Symptoms, Diagnosis, and Complications
